These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8487254)

  • 1. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
    Strobl GR; von Kruedener S; Stöckigt J; Guengerich FP; Wolff T
    J Med Chem; 1993 Apr; 36(9):1136-45. PubMed ID: 8487254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.
    Masimirembwa CM; Hasler JA; Johansson I
    Eur J Clin Pharmacol; 1995; 48(1):35-8. PubMed ID: 7621845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
    de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
    Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
    Prueksaritanont T; Dwyer LM; Cribb AE
    Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.
    Hutzler JM; Walker GS; Wienkers LC
    Chem Res Toxicol; 2003 Apr; 16(4):450-9. PubMed ID: 12703961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.
    Halliday RC; Jones BC; Smith DA; Kitteringham NR; Park BK
    Br J Clin Pharmacol; 1995 Oct; 40(4):369-78. PubMed ID: 8554939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
    Ching MS; Blake CL; Ghabrial H; Ellis SW; Lennard MS; Tucker GT; Smallwood RA
    Biochem Pharmacol; 1995 Sep; 50(6):833-7. PubMed ID: 7575645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
    Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
    Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
    Wang A; Stout CD; Zhang Q; Johnson EF
    J Biol Chem; 2015 Feb; 290(8):5092-5104. PubMed ID: 25555909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.
    Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
    J Pharmacol Exp Ther; 1999 Jul; 290(1):429-38. PubMed ID: 10381809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
    Mankowski DC
    Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
    Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
    Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modelling of human CYP2D6 and molecular docking of a series of ajmalicine- and quinidine-like inhibitors.
    Saraceno M; Coi A; Bianucci AM
    Int J Biol Macromol; 2008 May; 42(4):362-71. PubMed ID: 18346782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A predictive model for substrates of cytochrome P450-debrisoquine (2D6).
    Koymans L; Vermeulen NP; van Acker SA; te Koppele JM; Heykants JJ; Lavrijsen K; Meuldermans W; Donné-Op den Kelder GM
    Chem Res Toxicol; 1992; 5(2):211-9. PubMed ID: 1379482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450.
    Stevens JC; Wrighton SA
    J Pharmacol Exp Ther; 1993 Aug; 266(2):964-71. PubMed ID: 8355218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.
    Guengerich FP; Miller GP; Hanna IH; Martin MV; Léger S; Black C; Chauret N; Silva JM; Trimble LA; Yergey JA; Nicoll-Griffith DA
    Biochemistry; 2002 Sep; 41(36):11025-34. PubMed ID: 12206675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
    von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
    J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes.
    Mimura M; Yamazaki H; Sugahara C; Hiroi T; Funae Y; Shimada T
    Biochem Pharmacol; 1994 Jun; 47(11):1957-63. PubMed ID: 7912070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.